Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 53 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 19, 2022 | clinicaltrials |
| NCT02639546 | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors(iMATRIXcobi) | completed | Phase 1 / Phase 2 | 56 | Hoffmann-La RocheINDUSTRY | 7 | Sep 16, 2022 |
| clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT02130466 | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | completed | Phase 1 / Phase 2 | 184 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2022 | clinicaltrials |
| NCT02303028 | Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours(TOPAZ) | completed | Phase 1 / Phase 2 | 30 | The Hospital for Sick ChildrenOTHER | 1 | Jun 28, 2022 | clinicaltrials |
| NCT00073892 | PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 44 | Cellxpert Biotechnology Corp.INDUSTRY | 2 | Jun 27, 2022 | clinicaltrials |
| NCT03913741 | A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies(innovaTV 206) | completed | Phase 1 / Phase 2 | 23 | GenmabINDUSTRY | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02447419 | Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors | completed | Phase 2 | 16 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03551795 | Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor | completed | Phase 1 / Phase 2 | 8 | Xiaoyan ZhangOTHER_GOV | 1 | May 9, 2022 | clinicaltrials |
| NCT04200404 | A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CStone PharmaceuticalsINDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT00855803 | Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis | completed | Phase 2 | 35 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT01515306 | A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors | completed | Phase 2 | 48 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03454620 | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | completed | Phase 1 / Phase 2 | 53 | Green Cross CorporationINDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02460224 | Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 / Phase 2 | 490 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 10, 2022 | clinicaltrials |
| NCT03322384 | UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma | completed | Phase 1 / Phase 2 | 20 | University of California, DavisOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT02318277 | A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) | completed | Phase 1 / Phase 2 | 176 | Incyte CorporationINDUSTRY | 1 | Jan 13, 2022 | clinicaltrials |
| NCT03220854 | SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx | completed | Phase 2 | 5 | Virginia Commonwealth UniversityOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT01294670 | Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Nov 18, 2021 | clinicaltrials |
| NCT00049361 | Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases | completed | Phase 2 | — | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT02423343 | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 41 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 9, 2021 | clinicaltrials |
| NCT00003816 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | completed | Phase 2 / Phase 3 | 361 | Roswell Park Cancer InstituteOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT02869295 | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors(NKTR-214) | completed | Phase 1 / Phase 2 | 28 | Nektar TherapeuticsINDUSTRY | 1 | Jul 29, 2021 | clinicaltrials |
| NCT04180384 | A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients | completed | Phase 2 | 44 | Athenex, Inc.INDUSTRY | 4 | Jul 29, 2021 | clinicaltrials |
| NCT00700336 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | completed | Phase 1 / Phase 2 | 69 | CanBas Co. Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT01457118 | An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies | completed | Phase 2 | 27 | Nektar TherapeuticsINDUSTRY | 2 | Jul 12, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT04439240 | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2021 | clinicaltrials |
| NCT00452413 | A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | completed | Phase 1 / Phase 2 | 65 | Eli Lilly and CompanyINDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT01693562 | A Phase 1/2 Study to Evaluate MEDI4736 | completed | Phase 1 / Phase 2 | 1,022 | MedImmune LLCINDUSTRY | 9 | May 13, 2021 | clinicaltrials |
| NCT03264066 | A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors | completed | Phase 2 | 87 | Hoffmann-La RocheINDUSTRY | 6 | May 11, 2021 | clinicaltrials |
| NCT02281409 | Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT03017521 | K-BASKET, TAS-117, PI3K/AKT Gene Aberration | completed | Phase 2 | 13 | Yonsei UniversityOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT01002924 | Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010) | completed | Phase 2 | 1 | EndocyteINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT04439214 | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT02116777 | Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Mar 26, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT01178411 | An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols | completed | Phase 1 / Phase 2 | 60 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 0 | Mar 10, 2021 | clinicaltrials |
| NCT02953782 | Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer | completed | Phase 1 / Phase 2 | 78 | Gilead SciencesINDUSTRY | 1 | Mar 1, 2021 | clinicaltrials |
| NCT01989546 | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT01327612 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | completed | Phase 2 | 12 | AmgenINDUSTRY | 3 | Feb 21, 2021 | clinicaltrials |
| NCT01670097 | Dexamethasone Dyspnea Study | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT01554371 | Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 44 | University of California, San FranciscoOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01445080 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Feb 2, 2021 | clinicaltrials |
| NCT00600275 | A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 57 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 17, 2020 | clinicaltrials |
| NCT00031967 | Melatonin and Radiation Therapy in Treating Patients With Brain Metastases | completed | Phase 2 | — | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 22, 2020 | clinicaltrials |
| NCT01588821 | Cabozantinib in Advanced Solid Malignancies | completed | Phase 2 | 37 | Massachusetts General HospitalOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT02857920 | Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 45 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 14, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2022source: clinicaltrials